Cambridge Investment Research Advisors, Inc. Aclaris Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 41,873 shares of ACRS stock, worth $121,431. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,873
Previous 41,873
-0.0%
Holding current value
$121,431
Previous $46,000
4.35%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ACRS
# of Institutions
84Shares Held
50.7MCall Options Held
30.6KPut Options Held
1K-
Bml Capital Management, LLC Zionsville, IN14.3MShares$41.3 Million9.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.69MShares$13.6 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.37MShares$9.78 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.01MShares$8.72 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.75MShares$7.99 Million0.11% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $193M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...